Research and Markets: The Outlook for Pharmaceuticals in Central Asia - Bangladesh Pharmaceutical Exports Are Expected To Increase by 20%-25% by the End Of 2008

DUBLIN--(Business Wire)--
Research and Markets
(http://www.researchandmarkets.com/research/06d116/the_outlook_for_ph) has
announced the addition of the "The Outlook for Pharmaceuticals in Central Asia"
report to their offering.

The Outlook for Pharmaceutical Markets in Asia is a unique collection of
management reports from Espicom Business Intelligence. Each report provides
individual and highly-detailed analysis of each market, looking at the key
regulatory, political, economic and corporate developments in the wider context
of market structure, service and access. The reports are available individually,
or as a discounted collection, and prices include 4 completely updated reports
sent quarterly, plus comprehensive report sent annually. There are over 60
markets covered in the worldwide series.

Executive Summary

4 Key Markets Covered! Bangladesh China India Pakistan

Highlights from the region

INDIA India is a country of extremes. The vast majority of the population is
both rural and poor, although urban poverty is also a problem. Modern healthcare
technology and western style pharmaceuticals are not even an issue for millions
of people. On a national level, the Indian health system is ill-equipped to cope
with the rising number of elderly and the changing disease patterns, with an
average of just 0.7 hospital beds and 0.6 physicians per thousand population.
India faces the continuing challenge of fighting infectious diseases like
malaria, tuberculosis and leprosy alongside increases in lifestyle related
problems faced by the developed world, such as cancer, cardiovascular disease
and diabetes.

India has more US FDA approved laboratories than any other country outside the
USA. A number of US companies already source pharmaceutical raw materials from
India. In comparison with China, the wide use of English in commerce is mooted
as an advantage to US companies, along with India's tradition as an exporting
nation. India should prove to be a useful regional production base. Partnering
an Indian company may also provide a good route to commercialisation in targeted
markets such as Brazil or Russia, where Indian companies have an established
presence. In addition, India has a large and varied patient base along with the
necessary chemical and analytical skills at a comparatively low cost to make it
an attractive base for clinical trials. R&D alliances are already being forged
between multinationals and domestic companies.

CHINA Growing at a rate of around 8.5% per annum, China undoubtedly has one of
the fastest expanding pharmaceutical markets in the world. The country has the
largest population, officially estimated at over 1.3 billion in 2005, and one of
the world's biggest economies, with GDP estimated at US$4.1 trillion in 2008.
That said, the country is by no means an easy market to penetrate. Its sheer
size means per capita incomes are very low. The opening of the Chinese market
has seen the gap divide between rich and poor grow since the 1980s, and this is
evident in the healthcare system in China; with minimal funding from the
government, healthcare establishments rely on fees and the sale of medicines to
survive. It comes to no surprise then, that the majority of China's advanced
facilities and best trained staff are to be found in the larger, more affluent
cities like Beijing, Shanghai, Guangzhou and Tianjin. The Chinese pharmaceutical
industry tends to focus on the manufacture of cheap generics and copycat drugs
and counterfeiting remains a problem. Imports of pharmaceuticals, particularly
that of retail medicines, have been growing strongly in recently years, nearly
doubling in the period 2002-2006, and this trend looks set to continue in the
near future with strong fundamentals in place.

PAKISTAN The Pakistani pharmaceutical market remains beset with difficulties.
Strict government control over pricing has made many drugs uneconomical, with
the result that they either become available only on the black market at
inflated prices, or disappear completely. In this environment, manufacturers,
both local and foreign-owned, have proved unable to generate the profits needed
for capital investment. This is not helped by a regulatory system best described
as rudimentary. There is virtually no public drug reimbursement or IP
protection; patent law was officially tightened in December 2000, although the
effectiveness of this has been questioned. In 2002, further changes were made,
making Pakistan's IP laws even weaker. Drug prices are officially controlled,
although the government lacks the capacity to enforce its policies in this area.
Some price rises have been allowed since 2000, but the current government shows
little sign of enacting any serious reform of the pharmaceutical sector,
preferring to allege profiteering on the part of the pharmaceutical industry.

BANGLADESH Given the country's lack of spending power, the pharmaceutical
market, at US$682 million, remains tiny in comparison with the size of the
population. Pharmaceutical spending is amongst the lowest in the world in per
capita terms. Steadily improving economic performance, combined with a general
determination to boost the quality of healthcare, should lead to steady, if
unspectacular, market growth, although the nation is currently in the grips of
political turmoil. A military-backed interim government, in power since October
2006 has been forced to declare a state of emergency and in April 2007, two
prominent political figures and former leaders were exiled. Elections are
expected to take place by the end of 2008, in the meantime the army is
considering initiating martial law.

An increase in investment in Bangladesh by multinational pharmaceutical
manufacturers is anticipated to stimulate the sector. The revised National Drug
Policy was introduced in 2005 with the hope of attracting foreign multinational
investment and revitalising the health sector in the long term. In addition the
continually improving performance of Beximco, the leading domestic manufacturer,
offers encouraging signs for the future. In 2005 the company was listed on the
London Stock Exchange and hopes to move into the lucrative Western markets.
Bangladesh pharmaceutical exports are expected to increase by 20%-25% by the end
of 2008. The market is dominated by cheap, locally produced generic drugs used
for the treatment or prevention of basic illnesses and conditions.

Key Topics Covered:

* FOR EVERY MARKET, SENT QUARTERLY
* MARKET OUTLOOK
* FOR EVERY MARKET, SENT ANNUALLY
* BACKGROUND DATA
* HEALTHCARE SYSTEM
* ACCESSING THE PHARMA MARKET
* CONTACT DETAILS

For more information visit
http://www.researchandmarkets.com/research/06d116/the_outlook_for_ph

Source: Espicom Business Intelligence Ltd

Research and Markets
Laura Wood, Senior Manager,
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Copyright Business Wire 2009